Arcturus Therapeutics ( (ARCT) ) has released its Q1 earnings. Here is a breakdown of the information Arcturus Therapeutics presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Arcturus Therapeutics Holdings Inc., based in San Diego, California, is a commercial mRNA medicines and vaccines company known for its innovative RNA therapeutics platforms and the development of infectious disease vaccines, particularly in liver and respiratory rare diseases. The company has a global collaboration for mRNA vaccines and a joint venture in Japan focusing on mRNA vaccine and therapeutic manufacturing.
In its first quarter 2025 financial update, Arcturus Therapeutics reported a strategic focus on its mRNA therapeutics pipeline, which has extended its cash runway into 2028. The company is advancing its cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency programs, with significant progress in clinical trials expected in mid-2025. Additionally, Arcturus received a milestone payment from its partnership with CSL following the European Union approval of its COVID-19 vaccine, KOSTAIVE®.
Key financial highlights for the quarter include revenues of $29.4 million, a decrease from $38.0 million in the same period last year, primarily due to lower milestone revenues as KOSTAIVE transitions to the commercial phase. Operating expenses were reduced to $46.2 million from $68.4 million in the previous year, with research and development expenses also seeing a significant decline. The company reported a net loss of $14.1 million, an improvement from the $26.8 million loss in the first quarter of 2024.
Arcturus continues to make strides in its clinical programs, with the ARCT-032 CF study and ARCT-810 OTC deficiency study expected to yield interim data in 2025. The company also received U.S. FDA Fast Track Designation for its sa-mRNA vaccine candidate for Pandemic Influenza A Virus H5N1. These developments, alongside regulatory filings for KOSTAIVE in the UK and US, highlight Arcturus’ commitment to advancing its pipeline.
Looking ahead, Arcturus Therapeutics remains focused on its strategic priorities, with management optimistic about the potential of its mRNA therapeutics pipeline. The company’s financial position, bolstered by strategic collaborations and resource reallocation, is expected to support its operations and growth into 2028.